Usefulness of the Baseline Syntax Score to Predict 3-Year Outcome After Complete Revascularization by Percutaneous Coronary Intervention

American Journal of Cardiology

Volumn 118, Issue 5, 2016, Pages 641-646

  Kang, Jeehoon ^a   Park, Kyung Woo ^a   Han, Jung Kyu ^a   Yang, Han Mo ^a   Kang, Hyun Jae ^a   Koo, Bon Kwon ^a   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; BIOLOGICAL MARKER; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; AGE; AGED; ARTICLE; CLINICAL OUTCOME; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; FEMALE; HAZARD RATIO; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY (TOPIC); MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SYNTAX SCORE; BLOOD; BODY MASS; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; DRUG ELUTING STENT; HEART STROKE VOLUME; KAPLAN MEIER METHOD; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; REGISTER; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SOUTH KOREA; TREATMENT OUTCOME;

AGED; BIOMARKERS; BODY MASS INDEX; CORONARY ANGIOGRAPHY; CREATININE; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; REGISTRIES; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SIROLIMUS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84979673825     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2016.06.024     Document Type: Article

References (23)

1. 1 Park, K.W., Kang, J., Kang, S.H., Ahn, H.S., Lee, H.Y., Kang, H.J., Koo, B.K., Chae, I.H., Youn, T.J., Oh, B.H., Park, Y.B., Kandzari, D.E., Kim, H.S., Usefulness of the SYNTAX and clinical SYNTAX scores in predicting clinical outcome after unrestricted use of sirolimus- and everolimus-eluting stents. Circ J 77 (2013), 2912–2921.
2. 2 Farooq, V., Serruys, P.W., Bourantas, C.V., Zhang, Y., Muramatsu, T., Feldman, T., Holmes, D.R., Mack, M., Morice, M.C., Stahle, E., Colombo, A., de Vries, T., Morel, M.A., Dawkins, K.D., Kappetein, A.P., Mohr, F.W., Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation 128 (2013), 141–151.
3. 3 Park, K.W., Kang, J., Kang, S.H., Ahn, H.S., Kang, H.J., Koo, B.K., Chae, I.H., Youn, T.J., Oh, B.H., Park, Y.B., Kandzari, D., Kim, H.S., The impact of residual coronary lesions on clinical outcomes after percutaneous coronary intervention: residual SYNTAX score after percutaneous coronary intervention in patients from the Efficacy of Xience/Promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) registry. Am Heart J 167 (2014), 384–392 e385.
4. 4 Conti, C.R., Coronary occlusion and ischemia reduction. JACC Cardiovasc Interv, 8, 2015, 1129.
5. 5 Vieira, R.D., Hueb, W., Gersh, B.J., Lima, E.G., Pereira, A.C., Rezende, P.C., Garzillo, C.L., Hueb, A.C., Favarato, D., Soares, P.R., Ramires, J.A., Kalil Filho, R., Effect of complete revascularization on 10-year survival of patients with stable multivessel coronary artery disease: MASS II trial. Circulation 126 (2012), S158–S163.
6. 6 Chung, J.W., Park, K.H., Lee, M.H., Park, K.W., Park, J.S., Kang, H.J., Koo, B.K., Kwon, Y.W., Kim, H.S., Benefit of complete revascularization in patients with multivessel coronary disease in the drug-eluting stent era. Circ J 76 (2012), 1624–1630.
7. 7 Ranucci, M., Castelvecchio, S., Menicanti, L., Frigiola, A., Pelissero, G., Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony. Circulation 119 (2009), 3053–3061.
8. 8 Serruys, P.W., Morice, M.C., Kappetein, A.P., Colombo, A., Holmes, D.R., Mack, M.J., Stahle, E., Feldman, T.E., van den Brand, M., Bass, E.J., Van Dyck, N., Leadley, K., Dawkins, K.D., Mohr, F.W., Investigators SYNTAX. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360 (2009), 961–972.
9. 9 Park, K.W., Chae, I.H., Lim, D.S., Han, K.R., Yang, H.M., Lee, H.Y., Kang, H.J., Koo, B.K., Ahn, T., Yoon, J.H., Jeong, M.H., Hong, T.J., Chung, W.Y., Jo, S.H., Choi, Y.J., Hur, S.H., Kwon, H.M., Jeon, D.W., Kim, B.O., Park, S.H., Lee, N.H., Jeon, H.K., Gwon, H.C., Jang, Y.S., Kim, H.S., Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus versus Cypher to Reduce Late Loss after Stenting) randomized trial. J Am Coll Cardiol 58 (2011), 1844–1854.
10. 10 Zimarino, M., Ricci, F., Romanello, M., Di Nicola, M., Corazzini, A., De Caterina, R., Complete myocardial revascularization confers a larger clinical benefit when performed with state-of-the-art techniques in high-risk patients with multivessel coronary artery disease: a meta-analysis of randomized and observational studies. Catheter Cardiovasc Interv 87 (2016), 3–12.
11. 11 Silber, S., Serruys, P.W., Leon, M.B., Meredith, I.T., Windecker, S., Neumann, F.J., Belardi, J., Widimsky, P., Massaro, J., Novack, V., Yeung, A.C., Saito, S., Mauri, L., Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program. JACC Cardiovasc Interv 6 (2013), 357–368.
12. 12 Muntner, P., Mann, D.M., Woodward, M., Choi, J.W., Stoler, R.C., Shimbo, D., Farkouh, M.E., Kim, M.C., Predictors of low clopidogrel adherence following percutaneous coronary intervention. Am J Cardiol 108 (2011), 822–827.
13. 13 Park, K.W., Kang, J., Park, J.J., Yang, H.M., Lee, H.Y., Kang, H.J., Koo, B.K., Oh, B.H., Park, Y.B., Kim, H.S., Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart 98 (2012), 1366–1372.
14. 14 Becker, R.C., Gibson, C.M., Jennings, L.K., Morrow, D.A., Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions. Am J Cardiol 106 (2010), S2–S3.
15. 15 Brugaletta, S., Magro, M., Simsek, C., Heo, J.H., de Boer, S., Ligthart, J., Witberg, K., Farooq, V., van Geuns, R.J., Schultz, C., van Mieghem, N., Regar, E., Zijlstra, F., Duckers, H.J., de Jaegere, P., Muller, J.E., van der Steen, A.F., Boersma, E., Garcia-Garcia, H.M., Serruys, P.W., Plaque compositional Syntax score: combining angiography and lipid burden in coronary artery disease. JACC Cardiovasc Imaging 5 (2012), S119–S121.
16. 16 Stone, G.W., Maehara, A., Lansky, A.J., de Bruyne, B., Cristea, E., Mintz, G.S., Mehran, R., McPherson, J., Farhat, N., Marso, S.P., Parise, H., Templin, B., White, R., Zhang, Z., Serruys, P.W., Investigators, P., A prospective natural-history study of coronary atherosclerosis. N Engl J Med 364 (2011), 226–235.
17. 17 Kubo, T., Maehara, A., Mintz, G.S., Doi, H., Tsujita, K., Choi, S.Y., Katoh, O., Nasu, K., Koenig, A., Pieper, M., Rogers, J.H., Wijns, W., Bose, D., Margolis, M.P., Moses, J.W., Stone, G.W., Leon, M.B., The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization. J Am Coll Cardiol 55 (2010), 1590–1597.
18. 18 Cassese, S., Byrne, R.A., Tada, T., Pinieck, S., Joner, M., Ibrahim, T., King, L.A., Fusaro, M., Laugwitz, K.L., Kastrati, A., Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart 100 (2014), 153–159.
19. 19 Zhao, Z., Witzenbichler, B., Mintz, G.S., Jaster, M., Choi, S.Y., Wu, X., He, Y., Margolis, M.P., Dressler, O., Cristea, E., Parise, H., Mehran, R., Stone, G.W., Maehara, A., Dynamic nature of nonculprit coronary artery lesion morphology in STEMI: a serial IVUS analysis from the HORIZONS-AMI trial. JACC Cardiovasc Imaging 6 (2013), 86–95.
20. 20 Calvert, P.A., Obaid, D.R., O'Sullivan, M., Shapiro, L.M., McNab, D., Densem, C.G., Schofield, P.M., Braganza, D., Clarke, S.C., Ray, K.K., West, N.E., Bennett, M.R., Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. JACC Cardiovasc Imaging 4 (2011), 894–901.
21. 21 Girasis, C., Garg, S., Raber, L., Sarno, G., Morel, M.A., Garcia-Garcia, H.M., Luscher, T.F., Serruys, P.W., Windecker, S., SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimus-eluting stent compared with pacliTAXel-eluting stent for coronary revascularization (SIRTAX) trial. Eur Heart J 32 (2011), 3115–3127.
22. 22 Singh, M., Rihal, C.S., Lennon, R.J., Garratt, K.N., Holmes, D.R. Jr., Comparison of Mayo Clinic risk score and American College of Cardiology/American Heart Association lesion classification in the prediction of adverse cardiovascular outcome following percutaneous coronary interventions. J Am Coll Cardiol 44 (2004), 357–361.
23. 23 Wykrzykowska, J.J., Garg, S., Girasis, C., de Vries, T., Morel, M.A., van Es, G.A., Buszman, P., Linke, A., Ischinger, T., Klauss, V., Corti, R., Eberli, F., Wijns, W., Morice, M.C., di Mario, C., van Geuns, R.J., Juni, P., Windecker, S., Serruys, P.W., Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial. J Am Coll Cardiol 56 (2010), 272–277.